Aligos Therapeutics, Inc. announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH). Dr. Blatt will provide a corporate update and discuss the company's entire pipeline, including ALG-055009, the coronavirus protease inhibitor ALG-097558, and Aligos' hepatitis B portfolio, on January 12, 2023, at 10:30 a.m. PT during the 41st Annual JP Morgan Healthcare Conference in San Francisco. Dr. Blatt's presentation will also be posted on the Aligos website at the time of the conference.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.455 USD | -3.44% |
|
-13.42% | -32.06% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.06% | 36.81M | |
+34.07% | 52.85B | |
-7.76% | 38.87B | |
+35.14% | 38.24B | |
-10.77% | 26.79B | |
+11.67% | 26.16B | |
-18.54% | 19.9B | |
+36.60% | 13.18B | |
+28.69% | 12.24B | |
-3.20% | 11.79B |
- Stock Market
- Equities
- ALGS Stock
- News Aligos Therapeutics, Inc.
- Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009